实用临床医药杂志2025，Vol.29Issue(10)：40-45,6.DOI:10.7619/jcmp.20244743
微小核糖核酸-125b、微小核糖核酸-142-5p和微小核糖核酸-140-3p与非小细胞肺癌患者程序性死亡受体1抗体治疗敏感性的关系
Relationships of microRNA-125b,microRNA-142-5p and microRNA-140-3p with sensitivity to programmed death-1 antibody therapy in patients with non-small cell lung cancer
摘要
Abstract
Objective To explore the relationships of microRNA-125b(miR-125b),microR-NA-142-5p(miR-142-5p)and microRNA-140-3p(miR-140-3p)with sensitivity to programmed death receptor-1(PD-1)antibody therapy in patients with non-small cell lung cancer(NSCLC)and their clinical significance.Methods A total of 219 NSCLC patients were selected and divided into sensitive group(n=92)and non-sensitive group(n=127)based on their sensitivity to PD-1 anti-body therapy.Serum levels of miR-125b,miR-142-5p and miR-140-3p were compared between the two groups.A new combined predictor was constructed using miR-125b,miR-142-5p,and miR-140-3p through a Logistic regression model.The predictive performance was evaluated using the receiver operating characteristic(ROC)curve,and data were substituted into the equation forpredictive vali-dation.Results The serum level of miR-125b was higher in the non-sensitive group than that in the sensitive group,while the serum levels of miR-142-5pand miR-140-3p were lower in the non-sensitive group(P＜0.05).Logistic regression analysis showed that an increased level of miR-125b was an independent risk factor for sensitivity to PD-1 antibody therapy in NSCLC patients(P＜0.05),while increased levels of miR-142-5p and miR-140-3p were independent protective factors(P＜0.05).The optimal cut-off value for the combined predictor was 0.117,with a sensitivity of 90.22％,a specificity of 85.04％,and an accuracy of 87.21％.ROC curve analysis revealed that the area under the curve(AUC)for the combined predictor in predicting sensitivity to PD-1 antibod-y therapy was 0.928,which was significantly larger than the AUCs of 0.825,0.817 and 0.772 for miR-125b,miR-142-5p and miR-140-3p,respectively(P＜0.05).A new equation was obtained by transforming the original Logistic regression equation,and data from three randomly selected pa-tients were substituted into the equation for calculation,with predictive results being consistent with clinical reality.Conclusion The miR-125b,miR-142-5p and miR-140-3p are all associated with sensitivity to PD-1 antibody therapy in NSCLC patients and can serve as biomarkers for predicting sensitivity to PD-1 antibody therapy.The combined predictor based on these three microRNAs can further enhance predictive value and provide more reliable reference information for clinical treat-ment decisions.关键词
微小核糖核酸-125b/微小核糖核酸-142-5p/微小核糖核酸-140-3p/非小细胞肺癌/程序性死亡受体1抗体/治疗敏感性/联合预测因子/Logistic回归模型Key words
microRNA-125b/microRNA-142-5p/microRNA-140-3p/non-small cell lung cancer/programmed death receptor-1 antibody/treatment sensitivity/combined predictors/Logistic regression model分类
临床医学引用本文复制引用
李静玉,朱彤,徐龙,郑振东..微小核糖核酸-125b、微小核糖核酸-142-5p和微小核糖核酸-140-3p与非小细胞肺癌患者程序性死亡受体1抗体治疗敏感性的关系[J].实用临床医药杂志,2025,29(10):40-45,6.基金项目
辽宁省科学技术计划项目(2021010238-427) （2021010238-427）
